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Abstract: Glycaemic control has shown beneficial outcomes for critically ill patients, but has been proven 
hard to achieve safely, increasing risk of hypoglycaemia. Patient metabolic variability is one of the main 
factor influencing glycaemic control safety and efficacy. STAR is a model-based glycaemic controller 
using a unique patient-specific risk-based dosing approach. STAR uses a 2D stochastic model, built from 
population data using kernel density methods, to determine potential forward future evolution in patient-
specific insulin sensitivity (SIn+1), based on its current value (SIn). 
This study uses virtual trial to compare the current 2D stochastic model used in STAR, with a new 3D 
stochastic model. The new 3D model also uses prior insulin sensitivity value (SIn-1) to determine 
distribution of likely future SIn+1. A total of 587 virtual patient glycaemic control episodes longer than 24 
hours from three different studies are used here. Safety (% blood glucose (BG) measurements < 4.0 and < 
2.2 mmol/L), performance (% time in the target 4.4-8.0 mmol/L band), insulin administration and nutrition 
delivery (% goal feed) are compared. 
Results show similar performance (90% BG in 4.4-8.0 mmol/L), and similar safety, with slightly higher % 
BG < 4.0 mmol/L (0.9 vs. 1.4%) and % BG < 2.2 mmol/L (0.02 vs. 0.03%) for the 3D model, was achieved 
for similar workload. The slightly lower median BG level (6.3 vs. 6.0 mmol/L) for the 3D stochastic model 
is explained by the higher median insulin rate administered (2.5 vs. 3.0 U/hr). More importantly, simulation 
results showed higher nutrition delivery using the 3D stochastic model (92 vs. 99 % goal feed). 
The new 3D stochastic model achieved similar safety and performance than the 2D stochastic model in 
these virtual simulations, while increasing the total calorific intake. This higher nutritional intake is 
potentially associated with improved outcome in intensive care units. The 3D stochastic model thus better 
characterises patient-specific metabolic variability, allowing more optimal insulin and nutritional dosing. 
Therefore, a pilot clinical trial using the new 3D stochastic model could be realised to assess and compared 
clinical outcomes using the new stochastic model. 
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
1. INTRODUCTION 
Hyperglycaemia, hypoglycaemia and highly variable blood 
glucose (BG) concentrations are associated with higher 
mortality, morbidity and length of stay in intensive care units 
(ICU) (Bagshaw et al., 2009; Capes et al., 2000; Egi et al., 
2006; Egi et al., 2010; Krinsley, 2008). Hyperglycaemia is a 
common complication for critically ill patients, suggesting 
glycaemic control (GC) to lower BG levels (McCowen et al., 
2001). GC using insulin therapy has shown positive outcomes, 
but has been proven difficult to achieve safely and effectively, 
significantly increasing risk of hypoglycaemia (Brunkhorst et 
al., 2008; Chase et al., 2010a; Finfer et al., 2009; Finfer et al., 
2012; Krinsley, 2004, 2005; Preiser et al., 2009; Reed et al., 
2007; Van den Berghe et al., 2001; Van den Berghe et al., 
2003). 
Safe and effective GC is required for all patient, and is a 
function of protocol design, not patient metabolic state 
(Uyttendaele et al., 2017). Patients metabolic variability is one 
of the most important factors making GC hard to achieve 
safely. Fixed table-based GC protocols thus often fail to 
provide safe control, completely lacking patient variability. 
Model-based GC protocols are thus used to assess intra- and 
inter- patient variability and offer patient-specific insulin 
therapy, directly managing risk (Chase et al., 2011). 
STAR is a model-based GC framework, which has shown 
promising results across different ICU settings (Evans et al., 
2012; Fisk et al., 2012; Stewart et al., 2016). STAR uses a 
unique patient-specific risk-based approach to titrate insulin 
and nutrition safely. Patient-specific insulin sensitivity (SI) is 
calculated using a clinically validated physiological model 
(Lin et al., 2011), and distribution of likely future SI variability 
is determined using a stochastic model (Lin et al., 2008). This 
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distribution of likely future SI allows to calculate potential 
future BG outcomes for a given intervention. STAR thus 
determines which intervention best overlaps a clinically 
chosen BG target band. 
Virtual trials (Chase et al., 2010b), using virtual patients, are 
used in this study to assess the impact of a new 3D stochastic 
model implemented in STAR. Such trials allow safety and 
performance assessment of GC outcomes for protocols tested 
on virtual cohorts, prior to clinical implementation. The 2D 
stochastic model uses current identified patient-specific SI 
value to compute distribution of likely future SI changes. 
Compared to its predecessor, the new 3D stochastic model is 
constructed using both previous and current SI values to 
forecast future SI variability. It thus uses the prior variability 
in SI to enhance prediction. BG outcomes are compared with 
the 2D stochastic model, to determine whether this new 3D 
model significantly improves safety and performance of 
STAR, by better characterizing inter-patient variability. 
2. METHODS 
2.1 STAR protocol and model-based insulin sensitivity 
The physiological model describing the glucose-insulin 
pharmacokinetics is schematically represented in Figure 1, and 
is defined (Lin, et al., 2011): 
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Where G(t) is blood glucose (mmol/L), I(t) is plasma insulin 
(mU/L), Q(t) is interstitial insulin (mU/L), P(t) is glucose from 
dextrose intake (mmol/min), and SI is insulin sensitivity 
(L/mU/min). Main clearance rates and parameters are defined 
in (Lin, et al., 2011; Pretty et al., 2014). 
The time-varying SI parameter describes the patient-specific 
metabolic response to insulin. SI is determined hourly from 
clinical data using integral-based fitting methods (Docherty et 
al., 2012; Hann et al., 2005), accounting for intra-patient 
variability. 
 
Figure 1 – Schematic representation of the glucose-insulin 
physiological model defined in Equations (1) – (3). 
2.2 2D vs. 3D stochastic model 
STAR uses a stochastic model, built on population data using 
kernel density estimations, to predict likely 1-3 hourly future 
changes in SI (Lin, et al., 2008). Based on the predicted 
distribution of future SI, the distribution of likely 
corresponding predicted future BG concentrations can be 
determined for a given intervention (Figure 2). STAR seeks 
the best intervention ensuring the 5th percentile of predicted 
BG ≥ 4.4 mmol/L, while maximizing the overlapping with the 
clinically specified target band (4.4-8.0 mmol/L). This unique 
risk-based dosing approach, significantly decreases risk of 
hypoglycaemia, while improving GC performance. STAR is 
the standard of care of two different ICUs, in Christchurch 
Hospital, New Zealand, and Gyula, Hungary.
 
Figure 2 – STAR uses stochastic models to forecast change in SI based on current SI value, and determines BG outcomes for 
given insulin and nutrition intervention. 




     
 
One important feature of STAR is its ability to modulates both 
insulin and nutrition inputs. Enteral nutrition can be lowered if 
insulin only intervention is not sufficient decrease BG levels, 
but STAR will always try to reach back 100% goal feed (GF) 
to maximise carbohydrates intake. Insulin is administered as 
intravenous boluses, with an equivalent maximum of 6U/hr, 
and authorizing up to 3U/hr in continuous infusion for 
consistent resistant patients. Enteral nutrition administration 
can be modulated between 30-100% of the total calorific GF if 
needed. As patient weight is not always known, 100% GF is 
estimated based on body frame size, age, and sex of the patient. 
More details can be found elsewhere (Stewart et al., 2018). 
The 2D stochastic model uses only current SI (SIn) as input to 
determine the distribution of likely future SI (SIn+1). The new 
3D stochastic model uses both previous (SIn-1) and current SIn 
values to determine the distribution of future SIn+1 
(Uyttendaele et al., 2018a). These stochastic models are made 
using local data density weighted Gaussian kernel estimation 
(Lin, et al., 2008). The resulting 5th-95th percentile prediction 
ranges are shown in Figure 3, where the 2D stochastic model 
is constant across all SIn-1, while the 3D model is variable 
across both SIn and SIn-1, yielding narrower and wider 
prediction ranges.  
 
Figure 3 – Comparison between 2D (green) and 3D (colour) 
stochastic model surfaces of the 5th (bottom) and 95th (top) 
percentile predictions of future SIn+1. The 2D model is constant 
across SIn-1, where the 3D model is different for every (SIn-1, 
SIn) pair, both narrower and wider across the range. 
Previous studies have shown the 3D model better captures SI 
variability, with tighter prediction bands for over 70% of the 
time, and showed stable patients tend to remain stable where 
variable patients are more likely to remain variable and are 
more variable than the 2D model represents (Uyttendaele, et 
al., 2018a; Uyttendaele et al., 2018b). This outcome suggests 
more aggressive dosing can be used for these more stable time 
periods, improving BG outcomes without compromising 
safety. 
2.3 Virtual trials and virtual patients 
Virtual trials are used to simulate GC protocols on virtual 
cohort, allowing to assess and compare BG outcomes for these 
protocols (Chase et al., 2018; Chase, et al., 2010b). Virtual 
patients are created from real patient clinical data, and are 
characterised by their SI profile over time. SI is considered 
treatment independent and hourly constant. Two different 
protocols can thus be simulated on a same virtual patient, 
resulting in different BG outcomes. Virtual trial simulations 
are a powerful tool allowing to avoid any undesired behaviour 
prior to clinical implementation. Virtual trials have been 
previously validated and shown generalisable across different 
ICUs practices (Dickson et al., 2017). 
A total of 587 virtual patient episodes longer than 24 hours are 
used in this study, totalling 65260 hours of GC. These virtual 
patient episodes were created using clinical data from 3 
different studies in 2 different countries (STAR protocol, 
Christchurch, New Zealand (Evans, et al., 2012); SPRINT 
protocol, Christchurch, New Zealand (Chase et al., 2008); 
STAR protocol, Gyula, Hungary (Benyo et al., 2012)). Patient 
demographic details are in (Stewart, et al., 2016). 
2.4 Analyses 
New 2D and 3D stochastic models are created using SI from 
411 (70%) random patient episodes out of the total 587. Virtual 
trial of STAR using the 2D and 3D stochastic models are 
simulated on the other 176 (30%) patient episodes, allowing 
fair GC outcome comparison. This overall process is realised 
three times, where patient episodes are each time randomly 
chosen for the training (70%) and testing (30%) sets, resulting 
thus in 528 simulated GC episodes. Thus, one virtual patient 
episode is possibly simulated three times if not used to build 
the stochastic models, but results will be different time to time 
according to the specific 2D and 3D stochastic models built. 
Safety and performance from GC simulation results are thus 
compared between both stochastic models. In this analysis, BG 
data is resampled hourly to allow fair comparison across 
different measurement intervals. Safety is evaluated by the 
%BG ≤ 4.4 mmol/L, %BG ≤ 4.0 mmol/L (mild 
hypoglycaemia) and %BG ≤ 2.2 mmol/L (severe 
hypoglycaemia). Performance is assessed by the percentage 
time in band (%BG with 4.4-8.0 mmol/L), and the median 
[IQR] per-patient BG. Insulin and nutrition %GF rates are also 
compared. Finally, workload is assessed by numbers of BG 
measurements per day, where a higher value would indicate 
more work for the change in stochastic models. 




     
 
 
Figure 4 – Simulation results comparison using the 2D (blue) and 3D (red) stochastic models for the same patient. Top panel 
shows the evolution of simulated BG, crosses represent BG measurements. Middle panel show this patient-specific SI profile. 
Bottom panel shows insulin boluses and nutrition rates over time. 
3. RESULTS 
Clinical and simulation results are summarised in Table 1 for 
each protocol. An example of the GC outcome results for each 
protocol is shown for one patient in Figure 4. Resampled BG, 
insulin rate, and percentage goal feed rate cumulative 
distribution functions (CDFs) are shown in Figure 5. 
Regarding performances, simulations results in Table 1 show 
both models achieved similar 90% time in the 4.4-8.0 mmol/L 
band for similar workload (11.6 vs. 11.7 measurements per 
day). The median [IQR] BG level achieved is slightly lower 
for the 3D stochastic model (6.3 [5.7, 6.9] vs. 6.0 [5.5, 6.7] 
mmol/L), reflected in Figure 5 (top). Additionally, both 
median [IQR] insulin and nutrition rates are higher for the 3D 
stochastic model (3.0 [1.5, 5.0] vs. 2.5 [1.5, 4.0] U/hr, and 92 
[70, 100] vs. 99 [66 100] %), also reflected in Figure 5 (middle 
and bottom). 
Concerning safety, the 3D stochastic model achieved lower % 
BG > 8.0 mmol/L (8 vs 7%), but higher % BG < 4.4 mmol/L 
(2 vs. 3%). More specifically, 0.5% higher BG < 4.0 mmol/L 
(mild hypoglycaemia) is observed for the 3D stochastic model, 
while very low % BG < 2.2 mmol/L (severe hypoglycaemia) 
for both models (0.02 vs. 0.03%) occurred. However, 12 
patients experienced severe hypoglycaemia with the 3D 
stochastic model, compared to 9 patients with the 2D 
stochastic model. 
These overall result trends can be seen in Figure 4, showing 
simulation results for one patient. BG (top) is similar, but 
slightly lower for the 3D stochastic model simulation (red). 
Insulin bolus sizes are often ~0.5 U/hr higher (bottom), as well 
as nutrition rates for the 3D stochastic model. The protocol 
simulations are based on identical SI profiles (middle), 
characterising this patient-specific metabolic evolution over 
time, thus really reflecting GC outcomes behaviour difference 
of these two protocols on the same underlying patient. 
 
Table 1 – Simulation results summary for safety and 
performance comparison. BG stats are calculated from 
hourly resampled BG as measurement intervals can differ 




Overall, these simulations show both protocols using the 2D 
or 3D stochastic model achieved safe and effective GC, with 
very low % BG < 4.4 mmol/L and high 90% time in the 4.4-
8.0 mmol/L target band. The main difference between the two 
approach remains in the insulin and nutrition rates 
administered. As expected, the higher insulin rate 
administered allowed higher per-patient median nutritional 
deliver rates as a function of goal feed rate, improving a 
delivery rate that is near the best in the world (Stewart, et al., 
2018). Therefore, the similar safety and performance, achieved 
with similar workload, were realised with overall greater 
carbohydrates delivery. 





















































 2D model 3D model 
# Patients 528 528 
Total hours 60246 60267 
Mean measurements per day 11.6 11.7 
BG level (mmol/L) 6.3 [5.7, 6.9] 6.0 [5.5, 6.7] 
Insulin rate (U/hr) 2.5 [1.5, 4.0] 3.0 [1.5, 5.0] 
Nutrition rate (%GF) 92 [70 100] 99 [66 100] 
% BG in 4.4-8.0 mmol/L 90 90 
% BG in 8.0-10.0 mmol/L 6 5 
% BG > 10.0 mmol/L 2 2 
% BG < 4.4 mmol/L 2 3 
% BG < 4.0 mmol/L 0.9 1.4 
% BG < 2.2 mmol/L 0.02 0.03 
# patients (%) < 2.2 mmol/L 9 (1.7) 12 (2.3) 
 




     
 
 
Figure 5 – Cohort resampled BG, insulin rate, and %GF CDFs 
comparison between simulations. 
A recent study showed STAR capacity to deliver nutrition 
rates better than 158 ICUs in 20 different countries (Stewart, 
et al., 2018), which may be associated with improved clinical 
outcomes in ICU (Heyland et al., 2011). In this study, the new 
3D stochastic model provided even better carbohydrate 
delivery compared to the previous 2D stochastic model. 
As explained, previous analysis on the new 3D stochastic 
model has shown the 3D stochastic model has consistently 
tighter prediction bands more than 70% of the time, 
particularly when SI is stable. These virtual trials confirm the 
accuracy on the forward prediction of SI variability of the new 
3D stochastic model, allowing more aggressive dosing, while 
increasing calories intake and ensuring both safety and 
performance. The 3D stochastic model thus improves the 
patient-specific GC approach in STAR. 
Based on these results, a pilot clinical trial can be realised to 
assess and compare safety, performance, nutrition delivery and 
workload of STAR using this new 3D stochastic model. 
5. CONCLUSIONS 
This study compared virtual trial results of STAR GC protocol 
using a 2D stochastic model, using only current SI to predict 
future SI, and a new 3D stochastic model using both current 
and previous SI to predict future SI changes. Simulations 
results showed similar safety and performance, while the 3D 
stochastic model version uses more aggressive insulin dosing. 
The main difference relies in the greater delivered % GF 
calorific content, for similar clinical workload. 
The 3D stochastic model implementation within the STAR 
framework can thus potentially lead to beneficial outcome in 
critically ill patients, as increased nutrition rate delivery is 
associated with improved clinical outcomes. A pilot clinical 
trial could thus assess and confirm these results. 
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